Servier Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SERVIER
SERVIER has two approved drugs.
There are fifteen US patents protecting SERVIER drugs.
Summary for Servier
| US Patents: | 15 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Servier
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | 9,968,595 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-001 | Aug 6, 2024 | RX | Yes | No | 9,579,324 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-002 | Aug 6, 2024 | RX | Yes | Yes | 11,844,758 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-001 | Aug 6, 2024 | RX | Yes | No | 11,345,677 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Servier Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 723859 | ⤷ Start Trial |
| Costa Rica | 20170097 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2013107291 | ⤷ Start Trial |
| Japan | 2021191785 | ⤷ Start Trial |
| Costa Rica | 20170097 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Servier Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2804851 | CA 2023 00025 | Denmark | ⤷ Start Trial | PRODUCT NAME: IVOSIDENIB ELLER ET FARMACEUTISK ACCEPTABELT SALT, TAUTOMER, ISOTOPOLOG ELLER HYDRAT DERAF; REG. NO/DATE: EU/1/23/1728 20230508 |
| 2804851 | 122023000051 | Germany | ⤷ Start Trial | PRODUCT NAME: LVOSIDENIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ, TAUTOMER, ISOTOPOLOG ODER HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/23/1728 20230504 |
| 2804851 | C202330033 | Spain | ⤷ Start Trial | PRODUCT NAME: IVOSIDENIB O UNA SAL, TAUTOMERO, ISOTOPOLOGO O HIDRATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1728; DATE OF AUTHORISATION: 20230504; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1728; DATE OF FIRST AUTHORISATION IN EEA: 20230504 |
| 2804851 | C02804851/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: IVOSIDENIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69077 13.06.2024 |
| 2804851 | 2023C/534 | Belgium | ⤷ Start Trial | PRODUCT NAME: IVOSIDENIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, TAUTOMEER, ISOTOPOLOOG OF HYDRAAT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1728 20230508 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
